Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | MC3R | P41968 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30881052 | 0.85 | LMNA (0.42) | LMNATSHRMAPK1SMN1; SMN2MAPT | |
| SCHEMBL8610051 | 0.85 | LMNA (0.42) | LMNATSHRMAPK1SMN1; SMN2CA1 | |
| Iocarmic Acid SCHEMBL38580 | 0.84 | TSHR (0.56) | LMNATSHRMAPK1SMN1; SMN2CYP3A4 | |
| Iosefamic Acid SCHEMBL29400390 | 0.82 | TSHR (0.55) | LMNATSHRMAPK1SMN1; SMN2ALDH1A1 | |
| Iosefamic Acid SCHEMBL29648519 | 0.82 | TSHR (0.55) | LMNATSHRMAPK1SMN1; SMN2ALDH1A1 | |
| Iosefamic Acid SCHEMBL38639 | 0.82 | TSHR (0.55) | LMNATSHRMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL11406813 | 0.81 | LMNA (0.47) | LMNATSHRMAPK1CYP2C19SMN1; SMN2 | |
| Iothalamic Acid SCHEMBL29746594 | 0.80 | LMNA (0.56) | LMNATSHRMAPK1SMN1; SMN2 | |
| Iothalamic Acid SCHEMBL38419 | 0.80 | LMNA (0.56) | LMNATSHRMAPK1SMN1; SMN2 | |
| SCHEMBL11292715 | 0.79 | LMNA (0.36) | LMNATSHRMAPK1ALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125054-A2 | PARTIALLY BIOABSORBABLE IMPLANT | CINVENTION AG (DE) | 2009-12-02 | — | — | EP | disclosed |
| EP-2120807-A2 | DEGRADABLE RESERVOIR IMPLANTS | CINVENTION AG (DE) | 2009-11-25 | — | — | EP | disclosed |
| EP-2117613-A1 | CARBON STENTS | CINVENTION AG (DE) | 2009-11-18 | — | — | EP | disclosed |
| EP-2111482-A2 | MEDICAL DEVICES WITH EXTENDED OR MULTIPLE RESERVOIRS | CINVENTION AG (DE) | 2009-10-28 | — | — | EP | disclosed |
| EP-2104472-A1 | POROUS, DEGRADABLE IMPLANT MADE BY POWDER MOLDING | CINVENTION AG (DE) | 2009-09-30 | — | — | EP | disclosed |
| EP-2104473-A1 | POROUS, NON-DEGRADABLE IMPLANT MADE BY POWDER MOLDING | CINVENTION AG (DE) | 2009-09-30 | — | — | EP | disclosed |
| US-20090192592-A1 | POROUS IMPLANT STRUCTURE | CINVENTION AG (DE) | 2009-07-30 | — | — | US | disclosed |
| WO-2008122594-A2 | PARTIALLY BIODEGRADABLE THERAPEUTIC IMPLANT FOR BONE AND CARTILAGE REPAIR | CINVENTION AG (DE) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122596-A2 | CURABLE THERAPEUTIC IMPLANT COMPOSITION | CINVENTION AG (DE) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122595-A2 | BIODEGRADABLE THERAPEUTIC IMPLANT FOR BONE OR CARTILAGE REPAIR | CINVENTION AG (DE) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008087213-A1 | POROUS, DEGRADABLE IMPLANT MADE BY POWDER MOLDING | CINVENTION AG (DE) | 2008-07-24 | — | — | WO | disclosed |
| EP-1830902-A2 | COMBINATION COMPRISING AN AGENT PROVIDING A SIGNAL, AN IMPLANT MATERIAL AND A DRUG | CINVENTION AG (DE) | 2007-09-12 | — | — | EP | disclosed |
| US-20060177379-A1 | Composition comprising an agent providing a signal, an implant material and a drug | CINVENTION AG (DE) | 2006-08-10 | — | — | US | disclosed |
| WO-2006069677-A2 | COMBINATION COMPRISING AN AGENT PROVIDING A SIGNAL, AN IMPLANT MATERIAL AND A DRUG | CINVENTION AG (DE) | 2006-07-06 | — | — | WO | disclosed |
| US-20020159951-A1 | Novel targeted compositions for diagnostic and therapeutic use | IMARX THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-5346690-A | Composition of a superparamagnetic or ferromagnetic particle and an X-ray contrast agent for MRI | NYCOMED IMAGING AS (NO) | 1994-09-13 | — | — | US | disclosed |
| EP-0414288-B1 | Contrast media | NYCOMED IMAGING AS (NO) | 1994-03-23 | — | — | EP | disclosed |
| EP-0414287-B1 | Particulate contrast media | NYCOMED IMAGING AS (NO) | 1994-01-19 | — | — | EP | disclosed |
| EP-0473729-A1 | CONTRAST MEDIA | NYCOMED AS (NO) | 1992-03-11 | — | — | EP | disclosed |
| WO-1991001149-A1 | CONTRAST MEDIA | NYCOMED AS (NO) | 1991-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020159951-A1 | Novel targeted compositions for diagnostic and therapeutic use | FABP3, SELPLG, ASGR1 | LMNA 589/4885TSHR 999/4885MAPK1 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.